Isocarboxazid. Efficacy and tolerance.


Journal Article

In a double-blind study, isocarboxazid was found to have greater efficacy than placebo. Patients with weight gain, increased appetite, and increased sleep responded particularly well, with a rapid onset of improvement that was apparent by one week. Their response to placebo was poor. Using a flexible dose, the modal range was 30-60 mg per day. Higher doses were poorly tolerated. At the doses used, side effects were generally mild, the most common being dizziness and myoclonus.

Full Text

Duke Authors

Cited Authors

  • Davidson, J; Turnbull, C

Published Date

  • May 1, 1983

Published In

Volume / Issue

  • 5 / 2

Start / End Page

  • 183 - 189

PubMed ID

  • 6222098

Pubmed Central ID

  • 6222098

International Standard Serial Number (ISSN)

  • 0165-0327

Digital Object Identifier (DOI)

  • 10.1016/0165-0327(83)90012-5


  • eng

Conference Location

  • Netherlands